Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Holderried, Tobias A W
[Clear All Filters]
2024
Penack O
,
Peczynski C
,
Boreland W
,
Lemaitre J
,
H Reinhardt C
,
Afanasyeva K
,
Avenoso D
,
Holderried TAW
,
Kornblit BThomas
,
Gavriilaki E
, et al.
ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.
Bone Marrow Transplant. 2024.
PubMed
Google Scholar
2023
Holderried TAW
,
Hecker K
,
Reh L
,
Kirschner M
,
Walter J
,
Brossart P
,
Holderried M
.
The potential of eHealth for cancer patients-does COVID-19 pandemic change the attitude towards use of telemedicine services?
. PLoS One. 2023;18(2):e0280723.
PubMed
Google Scholar
2022
Goldschmidt H
,
Mai EK
,
Bertsch U
,
Fenk R
,
Nievergall E
,
Tichy D
,
Besemer B
,
Dürig J
,
Schroers R
,
von Metzler I
, et al.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase
. Lancet Haematol. 2022;9(11):e810-e821.
PubMed
Google Scholar
2021
Crysandt M
,
Soysal H
,
Jennes E
,
Holtick U
,
Mrotzek M
,
Rehnelt S
,
Holderried TAW
,
Wessiepe M
,
Kunter U
,
Wilop S
, et al.
Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility.
Eur J Haematol. 2021.
PubMed
Google Scholar